Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs

D O'Hagan, C Goldbeck, M Ugozzoli, G Ott, RL Burke - Vaccine, 1999 - Elsevier
D O'Hagan, C Goldbeck, M Ugozzoli, G Ott, RL Burke
Vaccine, 1999Elsevier
The ability of a genetically detoxified mutant of heat labile enterotoxin (LTK63) to act as a
mucosal adjuvant following intranasal immunization with recombinant gD2 has previously
been reported in mice [Ugozzoli M, O'Hagan DT, Ott GS. Intranasal immunization of mice
with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and
serum antibody responses. Immunol 1998; 93: 563–571.]. In the current studies, these
observations were extended to the guinea pig model. Immunized guinea pigs were …
The ability of a genetically detoxified mutant of heat labile enterotoxin (LTK63) to act as a mucosal adjuvant following intranasal immunization with recombinant gD2 has previously been reported in mice [Ugozzoli M, O'Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunol 1998;93:563–571.]. In the current studies, these observations were extended to the guinea pig model. Immunized guinea pigs were subsequently challenged intravaginally with HSV-2. Intranasal immunization with gD2 and LTK63 induced a significant reduction in disease severity and a reduction in mortality. However, only intramuscular immunization with a potent adjuvant (MF59) induced protection against the incidence of disease.
Elsevier